NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). If you currently own shares of Edwards stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=29704 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at case@rosenlegal.com. Why Rosen La. ...

Independent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the independent Data Safety Monitoring Review Board (DSMB) has recommended the continuation ...

PHILADELPHIA, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of STAAR Surgical Company (NASDAQ: STAA) (“STAAR” or the “Company”) shareholders to determine whether the proposal is fair to investors.  Click here for additional information: https://kaskelalaw.com/case/staar-surgical/  On August 5, 2025, STAAR announced that it had agreed to be acquired by Alcon at a price of $28.00 per share in cash. F ...

Question-and-Answer SessionGood. So you've been on the job kind of about 6 months now. So maybe if you think about the first 6 months and coming into Medtronic, curious how you're thinking about the business today and how you want investors to kind of think about your plan for kind of shareholder value creation from here and sort of the initial earnings here in the first 6 months?Thierry PietonExecutive VP & CFO Yes. So look, one of the reasons or some of the reasons I decided to join Medtronic is, first, I ...

Abbott Laboratories (NYSE:ABT) is included among the Best Retirement Stocks for a Dividend Stock Portfolio. Building Consistent Income in a Dividend Stock Portfolio with Abbott Laboratories (ABT) Photo by Dan Dennis on Unsplash Abbott Laboratories (NYSE:ABT) operates a broad business spanning four main areas: medical devices, established pharmaceuticals, diagnostics, and nutrition. With a strong global presence, its diversified structure helps balance performance when one segment experiences weakness. ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether DexCom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On September 18, 2025 ...

Key Takeaways HOLX will discontinue Fluoroscan InSight FD by Sept. 30, 2025 due to low margins and limited growth.Hologic's Skeletal Health sales rose 62.1% in Q3 on Horizon DXA ramp-up, boosting overall performance.HOLX narrowed the 2025 revenue guidance to $4.081-$4.091B after strong results and easing tariffs.Hologic’s (HOLX) Skeletal Health division has been driving positive contributions ever since the earlier supply challenges began to ease. Sales jumped 62.1% in the third quarter of fiscal 2025, driv ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...

Key Takeaways Medtronic secured FDA approval for its Altaviva implantable tibial neuromodulation device. MDT's device treats urge urinary incontinence through a minimally invasive ankle implant. MDT's Altaviva features a 15-year battery life, quick recharging, and MRI compatibility. Medtronic plc (MDT) recently received Food and Drug Administration (“FDA”) approval for the minimally invasive implantable tibial neuromodulation (ITNM) Altaviva device. The therapy is inserted near the ankle and designed to tre ...

Key Takeaways Boston Scientific expanded in oncology and hypertension with Intera Oncology and SoniVie deals. Acquisitions boosted BSX Q2 revenues by 450 basis points, strengthening therapeutic portfolios. BSX's WATCHMAN franchise grew 28% in Q2, aided by CE Mark for next-gen FLX Pro device. Boston Scientific (BSX) is poised for growth in the upcoming quarters, driven by its impressive strategic acquisitions. The long-term prospects of the WATCHMAN devices are encouraging. Meanwhile, headwinds like currency ...